Terms: = Brain cancer AND MITF, WS2A, ENSG00000187098, 4286 AND Treatment
4 results:
1. Whole transcriptome and proteome analyses identify potential targets and mechanisms underlying tumor treating fields against glioblastoma.
Xu S; Luo C; Chen D; Tang L; Chen L; Liu Z
Cell Death Dis; 2022 Aug; 13(8):721. PubMed ID: 35982032
[TBL] [Abstract] [Full Text] [Related]
2. Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease: a retrospective analysis for Japanese patients with activating EGFR mutations.
Nishie K; Kawaguchi T; Tamiya A; Mimori T; Takeuchi N; Matsuda Y; Omachi N; Asami K; Okishio K; Atagi S; Okuma T; Kubo A; Maruyama Y; Kudoh S; Takada M
J Thorac Oncol; 2012 Nov; 7(11):1722-7. PubMed ID: 23059777
[TBL] [Abstract] [Full Text] [Related]
3. Stage migration: results of lymph node dissection in the era of modern imaging and invasive staging for lung cancer.
Kirmani BH; Rintoul RC; Win T; Magee C; Magee L; Choong C; Wells FC; Coonar AS
Eur J Cardiothorac Surg; 2013 Jan; 43(1):104-9; discussion 109-10. PubMed ID: 22529185
[TBL] [Abstract] [Full Text] [Related]
4. Impact of targeting deviations on outcome in medulloblastoma: study of the French Society of Pediatric Oncology (SFOP).
Carrie C; Hoffstetter S; Gomez F; Moncho V; Doz F; Alapetite C; Murraciole X; Maire JP; Benhassel M; Chapet S; Quetin P; Kolodie H; Lagrange JL; Cuillere JC; Habrand JL
Int J Radiat Oncol Biol Phys; 1999 Sep; 45(2):435-9. PubMed ID: 10487567
[TBL] [Abstract] [Full Text] [Related]
